Menarini APAC signs licensing agreement with Daiichi Sankyo

Menarini Asia-Pacific (APAC) Holdings, part of the Italian global biopharmaceutical company

Menarini Group, has signed a multi-year exclusive licensing agreement to assume the registration, sales, marketing, and distribution of the orally administered gabapentinoid, mirogabalin (TARLIGE), in the Philippines, Malaysia and Singapore. TARLIGE was developed and is currently marketed in Japan by Daiichi Sankyo and is indicated for the treatment of peripheral neuropathic pain (PNP), including diabetic PNP and post-herpetic neuralgia. The drug binds to and modulates the α2δ-1 subunit of the voltage-gated calcium channels widely found in the nervous system in areas that mediate pain transmission and processing. Neuropathic pain, which refers to pain caused by a lesion or disease of the somatosensory nervous system, has been shown to be prevalent in the general population by as much as 7 to 8 per cent. Patients with neuropathic pain are more susceptible to high pain intensity with more comorbidities, such as depression, panic/anxiety disorder, and sleep disorders.